Regulated information

Q1 2013 sales

Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012.

Q2 2013 sales

Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like.

2012 sales up 5.0%

Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%.

Continued Sales Growth in the second Quarter of 2010

Vétoquinol recorded strong sales growth (+15.1%) in the first six months of 2010, driven mainly by an increase in organic growth.

2013 3rd quarter sales show organic growth

Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates.

Continued sales growth driven by sustained organic growth

April 22, 2010 (Lure, France) - Vétoquinol recorded a significant increase in sales in the first quarter of 2010, driven by sustained organic growth and the contribution of its Indian acquisition.

Strong Sales in the 3rd Quarter of 2010

Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.

Strong growth in 2009 Revenues: +7.6%

January 20, 2010 (Lure, France) - Vétoquinol recorded strong sales growth in 2009, despite an unfavourable exchange rate effect. The strength in sales is explained to a large extent by the contribution of acquisitions in Italy and India and by the resumption of organic growth, which held firm in the second half of 2009 despite the continuing weakness in the general economy. Revenues increased in all therapeutic classes and all geographic regions.

VÉTOQUINOL and JANSSEN ANIMAL HEALTH finalize an agreement for the exclusive distribution of SUROLAN® in the United States

January 14, 2010 (Lure, France) – As part of its strategy of expanding its sales in the American market, Vétoquinol is pleased to announce an agreement with Janssen Animal Health to distribute Surolan® in the United States, following its approval by the FDA in December 2009. Surolan® is a leading example of Vétoquinol’s strategic focus on anti-infective agents and its success in this area. Surolan® has an excellent reputation in Europe, where it has been a great success.